For the quarter ending 2026-03-31, MIRM made $159,882K in revenue. -$790,155K in net income. Net profit margin of -494.21%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product sales, net | 159,882 | 148,932 | 133,010 | 127,785 |
| Cost of sales | 28,805 | 28,264 | 25,537 | 23,421 |
| Research and development | 97,910 | 51,107 | 42,960 | 46,067 |
| Acquired in-process research and development | 726,302 | - | - | - |
| Selling, general and administrative | 96,330 | 74,128 | 61,910 | 63,286 |
| Total operating expenses | 949,347 | 153,499 | 130,407 | 132,774 |
| Loss from operations | -789,465 | -4,567 | 2,603 | -4,989 |
| Interest income | 3,401 | 3,420 | 3,251 | 3,033 |
| Interest expense | 3,616 | 3,598 | 3,606 | 3,589 |
| Loss from termination of revenue interest purchase agreement | - | 0 | - | - |
| Other income, net | 0 | -218 | 395 | 86 |
| Net loss before provision for income taxes | -789,680 | -4,963 | 2,643 | -5,459 |
| Provision for income taxes | 475 | 767 | -262 | 402 |
| Net loss | -790,155 | -5,730 | 2,905 | -5,861 |
| Basic EPS | -13.43 | -0.111 | 0.06 | -0.12 |
| Diluted EPS | -13.43 | -0.127 | 0.05 | -0.12 |
| Basic Average Shares | 58,851,021 | 51,538,104 | 50,639,231 | 49,726,823 |
| Diluted Average Shares | 58,851,021 | 45,183,494 | 56,993,841 | 49,726,823 |
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)